Vaccine developer Moderna may slow COVID trials to add at-risk minorities
The company said it has enrolled 21,411 participants in the study so far. It had 17,000 participants as of last week, with 24% from communities of color.
Full Article
Vaccine developer Moderna may slow COVID trials to add at-risk minorities
Jerusalem Post
0 shares
1 views
You might like
Related news coverage
Novavax to start late-stage trials for COVID-19 vaccine in UK
Novavax Inc (NASDAQ:NVAX) is set to start late-stage trials for its COVID-19 vaccine candidate in the UK. The US firm will enrol up..
Proactive Investors